Document is current
Any future updates will be listed below
-
Authors
Liu, Shirley Yuk-Wah
Wong, Vincent Wai-Sun
Wong, Simon Kin-Hung
Wong, Grace Lai-Hung
Lai, Carol Man-sze
Lam, Candice Chuen-Hing
Shu, Sally She-Ting
Chan, Henry Lik-Yuen
Ng, Enders Kwok-Wai
- License Information
-
More Information
Article History
Received: 10 November 2020
Accepted: 27 January 2021
First Online: 8 March 2021
Competing interests
: VW Wong has served as a consultant or advisory board member for 3V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Center for Outcomes Research in Liver Diseases, Echosens, Gilead Sciences, Hanmi Pharmaceutical, Intercept, Merck, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer, ProSciento, Sagimet Biosciences, TARGET-NASH, and Terns; and a speaker for AbbVie, Bristol-Myers Squibb, Echosens, and Gilead Sciences. He has also received an unrestricted grant from Gilead Sciences for fatty liver research. GL Wong has served as an advisory committee member for Gilead Sciences and Janssen, and as a speaker for Abbott, Abbvie, Ascletis, Bristol-Myers Squibb, Echosens, Gilead Sciences, Janssen and Roche. She has also received an unrestricted grant from Gilead Sciences for hepatitis research. HL Chan has served as an advisor and speaker for Gilead and Roche. All other authors do not have personal interests to disclose. There is no financial conflict of interests involved in this manuscript.
